FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileHikma Pharmaceuticals PLC
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
HKMPY
Hikma Pharmaceuticals PLC Stock AnalysisComprehensive stock analysis for Hikma Pharmaceuticals PLC (HKMPY) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisHKMPY
HKMPY
Hikma Pharmaceuticals PLC
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
HKMPY
Home🔹Stocks🔹Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC

🇺🇸HKMPY•OTC

Hikma Pharmaceuticals PLC

🇺🇸HKMPY•OTC
Market cap
$4.97B
Sentiment

Your view on HKMPY

Mkt Cap
$4.97B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Hikma Pharmaceuticals PLC

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Said Samih Taleb Darwazah
Headquarters
1 New Burlington Place, London, GB
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Said Samih Taleb Darwazah
Headquarters
1 New Burlington Place, London, GB
Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.

The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets.

The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally.

The company was founded in 1978 and is based in London, the United Kingdom.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

Fair value for Hikma Pharmaceuticals PLC from FRC's valuation model, read against the market price. HKMPY last traded at $45.06, 12.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Hikma Pharmaceuticals PLC. Starting points for Hikma Pharmaceuticals PLC: P/E 12.2, EPS $3.65, beta 0.71 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Hikma Pharmaceuticals PLC. Hikma Pharmaceuticals PLC does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Hikma Pharmaceuticals PLC. Trailing twelve-month EPS for Hikma Pharmaceuticals PLC stands at $3.65. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

As of Nov 12, 2026 · USD

Earnings Estimate

EPSCurrent QtrSep 2025Next QtrDec 2025Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.00$0.00$0.00$0.00
Low estimate$0.00$0.00$0.00$0.00
High estimate$0.00$0.00$0.00$0.00
No. of analysts0000
Year-ago EPS——$3.62—
Growth——-100.0%—

Revenue Estimate

RevenueCurrent QtrSep 2025Next QtrDec 2025Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1.69B$1.68B$3.45B$3.57B
Low estimate$1.69B$1.68B$3.42B$3.51B
High estimate$1.69B$1.68B$3.47B$3.62B
No. of analysts111010
Year-ago revenue——$3.36B—
Growth——+2.8%—

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Hikma Pharmaceuticals PLC. Hikma Pharmaceuticals PLC has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Hikma Pharmaceuticals PLC valued side by side against its closest peers. Hikma Pharmaceuticals PLC is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

News

Latest headlines and market coverage.

Latest headlines and company announcements for Hikma Pharmaceuticals PLC. Coverage tracks Hikma Pharmaceuticals PLC within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Hikma Pharmaceuticals PLC.

Peer companies

  • AMPHAmphastar Pharmaceuticals, Inc.
  • AMRXAmneal Pharmaceuticals, Inc.
  • ANIPANI Pharmaceuticals, Inc.
  • APNHYAspen Pharmacare Holdings Limited
  • BHCBausch Health Companies Inc.
  • ELTPElite Pharmaceuticals, Inc.
  • HLTRFHLS Therapeutics Inc.
  • MKKGYMerck KGaA

More Drug Manufacturers - Specialty & Generic companies

  • STHZFStateHouse Holdings Inc.
  • STMHStem Holdings, Inc.
  • STSNStemsation International, Inc.
  • SUPNSupernus Pharmaceuticals, Inc.
  • SWDCFSwedencare AB (publ)
  • SWGHFSawai Group Holdings Co., Ltd.
  • SXTCChina SXT Pharmaceuticals, Inc.
  • SYUPAnbc, Inc.
  • TAKTakeda Pharmaceutical Company Limited
  • TCNAFTransCanna Holdings Inc.
  • TCNNFTrulieve Cannabis Corp.
  • TEVATeva Pharmaceutical Industries Limited
HKMPY Analysis
Good
Past1
Growth4
Health3
Profit3
Value5

News

Latest Market News